^
Association details:
| Biomarker: | AXL overexpression |
|---|---|
| Cancer: | Adenoid Cystic Carcinoma |
| Drug: | mipasetamab uzoptirine (ADCT-601) (DNA replication inhibitor, AXL-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB084 / 9 - AXL as a therapeutic target in adenoid cystic carcinoma: preclinical evaluation of AXL targeting antibody-drug conjugate (ADCT-601)
Published date:
03/09/2022
Excerpt:
In high AXL expressing ACCX6 model, a single dose of either 0.5 or 1.0 mg/kg ADCT-601 significantly suppressed tumor growth resulting 3/5 partial responders (PRs) at 1mg/kg and 2/5 PRs at 0.5 mg/kg...This study demonstrated that ADCT-601 induced a potent and specific in vitro and in-vivo anti-tumor activities in AXL expressing ACC models...
